Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
6.87
USD
|
+3.31%
|
|
-1.58%
|
-6.15%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
409.6
|
297.7
|
252.1
|
113
|
307.9
|
291.4
|
-
|
-
|
Enterprise Value (EV)
1 |
409.6
|
297.7
|
252.1
|
113
|
307.9
|
291.4
|
291.4
|
291.4
|
P/E ratio
|
-14.1
x
|
-6.73
x
|
-7.05
x
|
-3.82
x
|
-4.95
x
|
-4.43
x
|
-8.7
x
|
111
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
21
x
|
12.5
x
|
60.1
x
|
12.2
x
|
4.04
x
|
2.12
x
|
EV / Revenue
|
-
|
-
|
21
x
|
12.5
x
|
60.1
x
|
12.2
x
|
4.04
x
|
2.12
x
|
EV / EBITDA
|
-13.6
x
|
-
|
-
|
-
|
-4.72
x
|
-4.55
x
|
-9.56
x
|
-56.8
x
|
EV / FCF
|
-14.6
x
|
-9.4
x
|
-8.86
x
|
-5.96
x
|
-7.91
x
|
-4.43
x
|
-11.3
x
|
4.29
x
|
FCF Yield
|
-6.86%
|
-10.6%
|
-11.3%
|
-16.8%
|
-12.6%
|
-22.6%
|
-8.89%
|
23.3%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
25,775
|
25,866
|
27,519
|
41,094
|
42,065
|
42,420
|
-
|
-
|
Reference price
2 |
15.89
|
11.51
|
9.160
|
2.750
|
7.320
|
6.870
|
6.870
|
6.870
|
Announcement Date
|
3/13/20
|
3/4/21
|
3/2/22
|
3/6/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
12
|
9.032
|
5.124
|
23.95
|
72.18
|
137.3
|
EBITDA
1 |
-30.02
|
-
|
-
|
-
|
-65.23
|
-64.08
|
-30.5
|
-5.135
|
EBIT
1 |
-30.08
|
-40.18
|
-30.91
|
-21.3
|
-65.76
|
-68.94
|
-33.54
|
11.81
|
Operating Margin
|
-
|
-
|
-257.57%
|
-235.78%
|
-1,283.35%
|
-287.86%
|
-46.46%
|
8.6%
|
Earnings before Tax (EBT)
1 |
-28.21
|
-42.69
|
-35.08
|
-24.49
|
-67
|
-75.47
|
-38.08
|
12.3
|
Net income
1 |
-28.21
|
-42.69
|
-35.08
|
-24.49
|
-67
|
-76
|
-39.46
|
5.664
|
Net margin
|
-
|
-
|
-292.33%
|
-271.11%
|
-1,307.47%
|
-317.33%
|
-54.67%
|
4.12%
|
EPS
2 |
-1.130
|
-1.710
|
-1.300
|
-0.7200
|
-1.480
|
-1.552
|
-0.7900
|
0.0620
|
Free Cash Flow
1 |
-28.09
|
-31.68
|
-28.46
|
-18.95
|
-38.94
|
-65.8
|
-25.9
|
67.9
|
FCF margin
|
-
|
-
|
-237.21%
|
-209.83%
|
-759.93%
|
-274.75%
|
-35.88%
|
49.44%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1,198.88%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/13/20
|
3/4/21
|
3/2/22
|
3/6/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
0.431
|
0.214
|
8.319
|
0.068
|
0.037
|
0.182
|
2.917
|
1.988
|
2.651
|
4.746
|
7.007
|
9.662
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-11.77
|
-8.47
|
-7.41
|
-9.121
|
1.448
|
-6.211
|
-7.089
|
-11.62
|
-23.92
|
-23.14
|
-19.86
|
-18.46
|
-16.78
|
-14.56
|
Operating Margin
|
-
|
-
|
-1,719.26%
|
-4,262.15%
|
17.41%
|
-9,133.82%
|
-19,159.46%
|
-6,382.42%
|
-819.92%
|
-1,163.78%
|
-749.31%
|
-388.97%
|
-239.49%
|
-150.72%
|
Earnings before Tax (EBT)
1 |
-12.83
|
-9.54
|
-8.47
|
-10.17
|
0.083
|
-5.932
|
-6.589
|
-10.99
|
-24.8
|
-24.61
|
-21.07
|
-19.7
|
-18.35
|
-16.2
|
Net income
1 |
-12.83
|
-9.54
|
-8.47
|
-10.17
|
0.083
|
-5.932
|
-6.589
|
-10.99
|
-24.8
|
-24.61
|
-21.07
|
-19.7
|
-18.35
|
-16.2
|
Net margin
|
-
|
-
|
-1,965.2%
|
-4,751.4%
|
1%
|
-8,723.53%
|
-17,808.11%
|
-6,038.46%
|
-850.26%
|
-1,238.13%
|
-794.66%
|
-414.97%
|
-261.89%
|
-167.64%
|
EPS
2 |
-0.4700
|
-0.3500
|
-0.3100
|
-0.3700
|
-
|
-0.1400
|
-0.1500
|
-0.2400
|
-0.5400
|
-0.5300
|
-0.4520
|
-0.4080
|
-0.3620
|
-0.3160
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/12/21
|
3/2/22
|
5/9/22
|
8/11/22
|
11/7/22
|
3/6/23
|
5/9/23
|
8/8/23
|
11/9/23
|
2/29/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-28.1
|
-31.7
|
-28.5
|
-19
|
-38.9
|
-65.8
|
-25.9
|
67.9
|
ROE (net income / shareholders' equity)
|
-36.5%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-1.100
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.68
|
1.47
|
0.88
|
0.3
|
0.36
|
5
|
5
|
5
|
Capex / Sales
|
-
|
-
|
7.36%
|
3.34%
|
7.06%
|
20.88%
|
6.93%
|
3.64%
|
Announcement Date
|
3/13/20
|
3/4/21
|
3/2/22
|
3/6/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
6.87
USD Average target price
13.6
USD Spread / Average Target +97.96% Consensus |
1st Jan change
|
Capi.
|
---|
| -6.15% | 291M | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|